INTRODUCTION: 2-Methoxyestradiol (2ME2) is an endogenous metabolite of the human hormone, estrogen, which has been shown to possess anti-tumor activity. 2-Fluoroethoxyestradiol (2FEE2) and 2-fluoropropanoxyestradiol (2FPE2), novel analogs of 2-methoxyestradiol, were designed and synthesized to be utilized as F-18 radiotracers for positron emission tomography (PET), with which the bio-distribution and intratumoral accumulations of 2ME2 could be measured in vivo for potential translation to human use. METHODS: 2FEE2 and 2FPE2 were synthesized from 3,17beta-estradiol in five steps respectively. Drug-induced microtubule depolymerization, antiproliferative activity against human cancer cell lines and HIF-1alpha down-regulation by 2FEE2 and 2FPE2 were investigated to examine whether these molecules possess similar anti-tumor activities as 2-methoxyestradiol. 2-[(18)F]Fluoroethoxyestradiol was synthesized for PET. RESULTS: Novel 2ME2 analogs, 2FEE2 and 2FPE2, were synthesized in 29% and 22% overall yield, respectively. 2FEE2 and 2FPE2 showed microtubule depolymerization and cytotoxicities against the human ovarian carcinoma cell line, 1A9, and the human glioma cell line, LN229. HIF-1alpha was down-regulated by 2FEE2 and 2FPE2 under hypoxic conditions. 2FEE2 was chosen as an F-18 radiotracer candidate, since it showed stronger antiproliferative activity than 2ME2 and 2FPE2. 2-[(18)F]Fluoroethoxyestradiol (2[(18)F]FEE2) was prepared in 8.3% decay-corrected yield in 90 min, based on a production of H[(18)F]F with more than 98% radiochemical purity. CONCLUSIONS: 2FEE2 and 2FPE2 showed similar activity as 2ME2. 2[(18)F]FEE2 was synthesized to be utilized as a PET radiotracer to measure the biological efficacy of 2ME2 and its analogs in vivo.
INTRODUCTION:2-Methoxyestradiol (2ME2) is an endogenous metabolite of the human hormone, estrogen, which has been shown to possess anti-tumor activity. 2-Fluoroethoxyestradiol (2FEE2) and 2-fluoropropanoxyestradiol (2FPE2), novel analogs of 2-methoxyestradiol, were designed and synthesized to be utilized as F-18 radiotracers for positron emission tomography (PET), with which the bio-distribution and intratumoral accumulations of 2ME2 could be measured in vivo for potential translation to human use. METHODS: 2FEE2 and 2FPE2 were synthesized from 3,17beta-estradiol in five steps respectively. Drug-induced microtubule depolymerization, antiproliferative activity against humancancer cell lines and HIF-1alpha down-regulation by 2FEE2 and 2FPE2 were investigated to examine whether these molecules possess similar anti-tumor activities as 2-methoxyestradiol. 2-[(18)F]Fluoroethoxyestradiol was synthesized for PET. RESULTS: Novel 2ME2 analogs, 2FEE2 and 2FPE2, were synthesized in 29% and 22% overall yield, respectively. 2FEE2 and 2FPE2 showed microtubule depolymerization and cytotoxicities against the humanovarian carcinoma cell line, 1A9, and the humanglioma cell line, LN229. HIF-1alpha was down-regulated by 2FEE2 and 2FPE2 under hypoxic conditions. 2FEE2 was chosen as an F-18 radiotracer candidate, since it showed stronger antiproliferative activity than 2ME2 and 2FPE2. 2-[(18)F]Fluoroethoxyestradiol (2[(18)F]FEE2) was prepared in 8.3% decay-corrected yield in 90 min, based on a production of H[(18)F]F with more than 98% radiochemical purity. CONCLUSIONS: 2FEE2 and 2FPE2 showed similar activity as 2ME2. 2[(18)F]FEE2 was synthesized to be utilized as a PET radiotracer to measure the biological efficacy of 2ME2 and its analogs in vivo.
Authors: Seung-Hee Kang; Heidi T Cho; Sarojini Devi; Zhaobin Zhang; Daniel Escuin; Zhongxing Liang; Hui Mao; Daniel J Brat; Jeffrey J Olson; Jonathan W Simons; Theresa M Lavallee; Paraskevi Giannakakou; Erwin G Van Meir; Hyunsuk Shim Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: Jehana James; Daryl J Murry; Anthony M Treston; Anna Maria Storniolo; George W Sledge; Carolyn Sidor; Kathy D Miller Journal: Invest New Drugs Date: 2006-09-13 Impact factor: 3.850
Authors: K C Nicolaou; K Namoto; A Ritzén; T Ulven; M Shoji; J Li; G D'Amico; D Liotta; C T French; M Wartmann; K H Altmann; P Giannakakou Journal: J Am Chem Soc Date: 2001-09-26 Impact factor: 15.419
Authors: M Cushman; H M He; J A Katzenellenbogen; R K Varma; E Hamel; C M Lin; S Ram; Y P Sachdeva Journal: J Med Chem Date: 1997-07-18 Impact factor: 7.446
Authors: Ronald J Voll; Jonathan McConathy; Michael S Waldrep; Ronald J Crowe; Mark M Goodman Journal: Appl Radiat Isot Date: 2005-09 Impact factor: 1.513
Authors: Justin L Ricker; Zhong Chen; Xin Ping Yang; Victor S Pribluda; Glenn M Swartz; Carter Van Waes Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531